The organ-on-chip market is anticipated to grow at a CAGR of 21.3% till 2035
In order to overcome the limitations and challenges related to animal testing, researchers and industry stakeholders are gradually adopting organ-on-chip products and technologies, which offer multiple benefits over conventional systems.
Roots Analysis has announced the addition of “Organ-on-Chip Market, 2022-2035: Focus on Products and Technologies” report to its list of offerings.
With the introduction of FDA Modernization Act in 2021, the use of animal models for preclinical testing is being discouraged in the pharmaceutical industry. Several players have opted to modernize their conventional testing models with organ-on-chip products and technologies. These novel products have the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. In addition, these organ-on-chip models not only reduce the need for animal testing model but are also capable of speeding-up the research and precise evaluation of drug toxicity and cellular responses.
For additional details, please visit https://www.rootsanalysis.com/....reports/organ-on-a-c